All Posts By

Smartkarma Daily Briefs

Daily Brief Credit: H&H International – Earnings Flash – FY 2022 Results – Lucror Analytics and more

By | Credit, Daily Briefs

In today’s briefing:

  • H&H International – Earnings Flash – FY 2022 Results – Lucror Analytics
  • Europe HY Trade Book – March 2023 – Lucror Analytics
  • Morning Views Asia:
  • Quest Diagnostics Incorporated: Detailed Credit Analysis & Financial Strength Evaluation Report
  • Zimmer Biomet Holdings Inc.: Detailed Credit Analysis & Financial Strength Evaluation Report

H&H International – Earnings Flash – FY 2022 Results – Lucror Analytics

By Charles Macgregor

H&H International has released reasonable FY 2022 results, despite the challenging macro economy and operating conditions during the year. Revenue rose more than 10% y-o-y to c. CNY 12.8 bn, mainly due to the full-year inclusion of Zesty Paws in the US. The gross profit margin contracted 2.5 ppts to 60.3%. Debt/EBITDA remained elevated at 5.7x as at FYE 2022. Liquidity is sound, with a cash balance of over CNY 2 bn and short-term debt of only CNY 1 bn.

The company aims to reduce net leverage to below 2.0x within three years. In our view, this plan is aggressive albeit attainable.


Europe HY Trade Book – March 2023 – Lucror Analytics

By Charles Macgregor

The Europe HY Trade Book for March 2023 includes high-conviction trade ideas drawn from our European HY coverage universe, along with relative-value scatter plots and tables by industry.


Morning Views Asia:

By Charles Macgregor

Lucror Analytics Morning Views comprise our fundamental credit analysis, opinions and trade recommendations on high yield issuers in the region, based on key company-specific developments in the past 24 hours. Our Morning Views include a section with a brief market commentary, key market indicators and a macroeconomic and corporate event calendar.


    Quest Diagnostics Incorporated: Detailed Credit Analysis & Financial Strength Evaluation Report

    By Baptista Research

    • Quest Diagnostics Incorporated is a well-known provider of diagnostic information services.
    • The company produced significant double-digit growth in prenatal genetics and pharmaceutical services for sophisticated diagnostics.
    • Baptista Research looks to evaluate the different credit strengths and credit risks of the company as well as a line-by-line analysis of the financial statements of the company for the past four years.

    Zimmer Biomet Holdings Inc.: Detailed Credit Analysis & Financial Strength Evaluation Report

    By Baptista Research

    • Zimmer Biomet Holdings is a global medical technology giant.
    • The management has been seeing positive comps across 2022 and saw good growth in major joints, with their entire global hip and knee business expanding well.
    • Baptista Research looks to evaluate the different credit strengths and credit risks of the company as well as a line-by-line analysis of the financial statements of the company for the past four years.

    💡 Before it’s here, it’s on Smartkarma

    Sign Up for Free

    The Smartkarma Preview Pass is your entry to the Independent Investment Research Network

    • ✓ Unlimited Research Summaries
    • ✓ Personalised Alerts
    • ✓ Custom Watchlists
    • ✓ Company Data and News
    • ✓ Events & Webinars

    Daily Brief ECM: National Storage REIT Placement – Past Deals Have Done Well but Stock Looks Toppish and more

    By | Daily Briefs, ECM

    In today’s briefing:

    • National Storage REIT Placement – Past Deals Have Done Well but Stock Looks Toppish
    • PNB Housing Finance Rights Issue – Finally Closing in on the Capital Raising
    • ZKH Group IPO: The Bear Case
    • Quest Diagnostics Incorporated: Initiation of Coverage – Business Strategy & Key Drivers
    • Snap-on Incorporated: Initiation of Coverage – Business Strategy & Recent Developments
    • Zimmer Biomet Holdings Inc.: Initiation of Coverage – Acquisition Of Embody & Other Drivers

    National Storage REIT Placement – Past Deals Have Done Well but Stock Looks Toppish

    By Sumeet Singh

    • National Storage REIT (NSR AU) (NSREIT) aims to raise around US$200m (A$300m) via an institutional placement.
    • Past deals have ended up doing well, however, the stock now appears toppish and it’s unclear if the deal was well flagged.
    • In this note, we will talk about the placement and run the deal through our ECM framework.

    PNB Housing Finance Rights Issue – Finally Closing in on the Capital Raising

    By Sumeet Singh

    • PNB Housing Finance Ltd (PNBHOUSI IN) (PHBHF) aims to raise up to US$300m via a rights issue in order to boost its capital base.
    • PNBHF is the housing finance arm of Punjab National Bank and is partly owned by Carlyle, with investments from General Atlantic as well.
    • In this note, we will talk about the rights issue and other deal dynamics.

    ZKH Group IPO: The Bear Case

    By Arun George

    • ZKH Group (ZKH US), a leading MRO (maintenance, repair, and operations) procurement service platform in China, is pre-marketing an NYSE IPO to raise US$200-300 million.
    • In ZKH Group IPO: The Bull Case, we highlighted the key elements of the bull case. In this note, we outline the bear case.
    • The key elements of the bear case rest on market share losses, slowing top-line growth, declining take rates and persistent cash burn.

    Quest Diagnostics Incorporated: Initiation of Coverage – Business Strategy & Key Drivers

    By Baptista Research

    • This is our first report on leading diagnostic service provider, Quest Diagnostics Incorporated.
    • The company produced significant double-digit growth in prenatal genetics and pharmaceutical services for sophisticated diagnostics.
    • Agilent Technologies further signed an agreement with Quest to make the Agilent Resolution ctDx FIRST liquid biopsy next-generation sequencing (NGS) test available to providers and patients across the U.S.

    Snap-on Incorporated: Initiation of Coverage – Business Strategy & Recent Developments

    By Baptista Research

    • This is our first report on Snap-on Incorporated, a well-known manufacturer and marketer of tools, equipment, diagnostics, repair information and systems solutions in the U.S.
    • The company’s last result was an all-around beat and its organic sales growth was in the double-digits with a particularly strong performance in the Repair Systems & Information Group, high single-digit gains in the Snap-on Tools Group, and low single-digit gains in the Commercial and Industrial Group.
    • Snap-on Tools Group sales were $542.7 million, up from $504.8 million a year ago, with a 9.6% increase in organic sales.

    Zimmer Biomet Holdings Inc.: Initiation of Coverage – Acquisition Of Embody & Other Drivers

    By Baptista Research

    • This is our first report on the global medical technology behemoth Zimmer Biomet Holdings.
    • They observed another quarter of year-over-year growth in major joints, with their entire global hip and knee business expanding by more than 8% and 10% on an ex FX basis.
    • We initiate coverage on the stock of Zimmer Biomet Holdings, Inc. with a ‘Hold’ rating.

    💡 Before it’s here, it’s on Smartkarma

    Sign Up for Free

    The Smartkarma Preview Pass is your entry to the Independent Investment Research Network

    • ✓ Unlimited Research Summaries
    • ✓ Personalised Alerts
    • ✓ Custom Watchlists
    • ✓ Company Data and News
    • ✓ Events & Webinars

    Daily Brief Equity Bottom-Up: Japan Banks: Markets Overreact to SVB’s Collapse and more

    By | Daily Briefs, Equity Bottom-Up

    In today’s briefing:

    • Japan Banks: Markets Overreact to SVB’s Collapse
    • ASICS (7936) | Running Is Recession Proof
    • Kuaishou (1024 HK) 4Q22 Earnings Preview: Weak Growth, But Loss to Shrink Significantly
    • Smartkarma Corporate Webinar | Uni-Asia: Creating Alternative Investment Opportunities in Asia
    • Poya International: Key Catalysts
    • Tencent (700 HK): 4Q22, Stop Decreasing WeChat Ad Recovered Earlier
    • CSPC Pharmaceutical (1093 HK): Double-Digit Sales and Profit Growth in 2022; MRNA Vaccine Approval
    • Tencent: Gradual Recovery in Earnings; Domestic Gaming to Resume Growth
    • Tongcheng Travel (780 HK): Best for Capturing Lower-Tier Cities’ Growth
    • TME: Social Entertainment Losing Its Importance with Top Line Growth Keep Declining

    Japan Banks: Markets Overreact to SVB’s Collapse

    By Oshadhi Kumarasiri

    • Following the collapse of SVB and Signature Bank last week, Japan’s big four banks have fallen by around 15% due to their exposure to US government bonds.
    • However, the Japanese banks have managed the interest rate risk far better than the collapsed US banks and therefore, we feel the price drop is unwarranted.
    • With Japan likely to scrap its zero rates policy, we think this could be a rather intriguing opportunity to make generous gains on the long side in Japan’s banking sector.

    ASICS (7936) | Running Is Recession Proof

    By Mark Chadwick

    • Good news from Nike’s Q3 report, which bodes well for Asics March quarter
    • Why was Nike’s stock down? Margins were down 330bps on inventory mark downs
    • Running is recession proof according to the footwear makers themselves

    Kuaishou (1024 HK) 4Q22 Earnings Preview: Weak Growth, But Loss to Shrink Significantly

    By Ming Lu

    • We believe both 4Q22 and 1Q23 can be weak quarters.
    • However, we believe operating losses will shrink significantly in 4Q22 and 2023.
    • We believe the stock has an upside of 77% for year end 2023.

    Smartkarma Corporate Webinar | Uni-Asia: Creating Alternative Investment Opportunities in Asia

    By Smartkarma Research

    For our next Corporate Webinar, in partnership with the SGX, we are glad to welcome Uni-Asia’s Group CFO, Lim Kai Ching.

    In the upcoming webinar, Kai Ching will share a short company presentation after which, he will engage in a fireside chat with Smartkarma Insight Provider, Osbert Tang, CFA . The Corporate Webinar will include a live Q&A session.

    The Corporate Webinar will be hosted on Tuesday, 4 April 2023, 17:00 SGT.

    About Uni-Asia

    Uni-Asia Group Limited is an alternative investment group specialising in creating alternative investment opportunities and providing integrated services relating to such investments. The Group’s alternative investment targets mainly include dry bulk ships and properties. The Group also has extensive know-how and a network relating to such alternative investments and provides services relating to these investments. The two main alternative asset classes the Group focuses on are Shipping and Property.


    Poya International: Key Catalysts

    By Douglas Kim

    • Three major catalysts of Poya International include easing of mask mandates/COVID restrictions, strong growth in dividends and earnings, and market share gains from competitors. 
    • Poya International is the dominant supplier of cosmetics, health care products, personal care products and household products in Taiwan.
    • The company continues to execute its business strategy better than its competitors and this is evidenced in its strong growth in profits and dividends in the past year. 

    Tencent (700 HK): 4Q22, Stop Decreasing WeChat Ad Recovered Earlier

    By Ming Lu

    • As we expected in the preview, total revenue stopped decreasing in 4Q22.
    • WeChat advertising recovered in 4Q22 earlier than we expected in the preview.
    • We believe game-related revenues will grow by 8% in 2023 and 19% in 2024.

    CSPC Pharmaceutical (1093 HK): Double-Digit Sales and Profit Growth in 2022; MRNA Vaccine Approval

    By Tina Banerjee

    • CSPC Pharmaceutical Group (1093 HK) reported 11% YoY revenue growth in 2022. The finished drug business maintained steady growth in 2022, with a continued increase in contribution from new products.
    • Within the next 5 years, more than 40 innovative drugs are expected to be approved, which will provide continuous momentum for the company’s development.
    • In March 2023, CSPC’s COVID-19 mRNA vaccine SYS6006 has become the first independently developed mRNA vaccine product in China that has been granted for emergency use.

    Tencent: Gradual Recovery in Earnings; Domestic Gaming to Resume Growth

    By Shifara Samsudeen, ACMA, CGMA

    • Tencent (700 HK) reported 4Q2022 results yesterday. Revenue increased 0.5% YoY to RMB145bn (vs consensus RMB)143.5bn while adjusted OP increased 30.1% YoY to RMB28.4bn (vs consensus RMB37.2bn).
    • Online advertising revenues saw a 14.8% YoY increase during 4Q2022 after 4-consecutive quarters of decline with January and February showing sustained recovery.
    • Though Domestic gaming revenues declined in 4Q2022, with new gaming licenses and international expansion, we expect gaming revenues to start growing from 1Q2023.

    Tongcheng Travel (780 HK): Best for Capturing Lower-Tier Cities’ Growth

    By Osbert Tang, CFA

    • While adjusted net profit of Tongcheng Travel Holdings Ltd (780 HK) plummeted in 4Q22, the positive momentum in 1Q23 as revealed supports a sharp recovery in FY23.
    • Its huge exposure to lower-tier cities will fuel outlook while increase in monetisation will support profitability rebound. Success at Blackwhale membership program is another growth engine.  
    • Management is confident that revenue growth and better efficiency will lead the return of FY23 margin to pre-pandemic levels. Net cash position (12% of share price) is an added strength. 

    TME: Social Entertainment Losing Its Importance with Top Line Growth Keep Declining

    By Shifara Samsudeen, ACMA, CGMA

    • Tencent Music (TME US) reported 4Q2022 results yesterday. Revenue decreased 2.4% YoY to RMB7.4bn (vs consensus RMB7.3bn) while reported operating profit more than doubled to RMB1.4bn (vs consensus RMB1.3bn).
    • Online music revenues grew 24% YoY while social entertainment business continues to see decline in paying users and ARPU. Margin improvements were driven by spending cuts.
    • Social Entertainment is losing its importance and the segment continues to remain under pressure due to competition from other platforms.

    💡 Before it’s here, it’s on Smartkarma

    Sign Up for Free

    The Smartkarma Preview Pass is your entry to the Independent Investment Research Network

    • ✓ Unlimited Research Summaries
    • ✓ Personalised Alerts
    • ✓ Custom Watchlists
    • ✓ Company Data and News
    • ✓ Events & Webinars

    Daily Brief Event-Driven: Rakuten Bank (5838 JP) IPO: Listing in April and more

    By | Daily Briefs, Event-Driven

    In today’s briefing:

    • Rakuten Bank (5838 JP) IPO: Listing in April, TPX Inclusion in May, MSCI SC in August
    • Rakuten Bank (5838 JP) – Another Net-Bank IPO, This One With TOPIX and Other Index Inclusions
    • MBK/Unison Launch ANOTHER Tender on Osstem Implant (048260 KS) To Squeeze Out Minorities
    • MBK/Unison Capital Announces a Second Tender Offer for Osstem Implant to Take It Private
    • StubWorld: Impairments Weigh Down Kingsoft Solid Results
    • Quiddity Leaderboard-DAX Jun 23: Fresenius, Lufthansa, Covestro, Continental & Others
    • Korea Small Cap Gem #20: BYC
    • Jiangnan Group (1366 HK): Irrevocable from the Shareholder with a Blocking Stake
    • Liberty/Telenet: Intended Offer for Minorities
    • Hindustan Aeronautics (HNAL IN) Offer for Sale: Buy Ahead of Potential MSCI Inclusion

    Rakuten Bank (5838 JP) IPO: Listing in April, TPX Inclusion in May, MSCI SC in August

    By Brian Freitas

    • Rakuten Bank (EBANKZ JP)‘s listing has been approved by the JPX and the stock is expected to start trading on the Prime Market from 21 April.
    • News reports indicate a raise of US$800mn (JPY 106.8bn) at the mid-point of the IPO range, valuing the company at JPY 305bn (US$2.3bn). 
    • The stock should be added to the TPX INDEX at the close on 30 May where trackers will need to buy over 14% of the stock issued in the IPO.

    Rakuten Bank (5838 JP) – Another Net-Bank IPO, This One With TOPIX and Other Index Inclusions

    By Travis Lundy


    MBK/Unison Launch ANOTHER Tender on Osstem Implant (048260 KS) To Squeeze Out Minorities

    By Travis Lundy


    MBK/Unison Capital Announces a Second Tender Offer for Osstem Implant to Take It Private

    By Douglas Kim

    • MBK/Unison Capital consortium announced a second tender offer for Osstem Implant (048260 KS) today in order to take the company private. 
    • The tender offer price is 190,000 won per share, which is the same price as the first tender offer price.
    • The number of shares for the tender offer is 1,654,916, accounting for 10.62% of the outstanding shares.

    StubWorld: Impairments Weigh Down Kingsoft Solid Results

    By David Blennerhassett

    • Despite the topline growth of 20%, Kingsoft Corp (3888 HK) recorded a loss in FY22 after a large impairment for its holding in Kingsoft Cloud (KC US).
    • Preceding my comments on Kingsoft are the weekly setup/unwind tables for Asia-Pacific Holdcos.
    • These relationships trade with a minimum liquidity of US$1mn, and a % market capitalisation >20%.

    Quiddity Leaderboard-DAX Jun 23: Fresenius, Lufthansa, Covestro, Continental & Others

    By Janaghan Jeyakumar, CFA

    • In this insight, we take a look at Quiddity’s estimates for the names leading the race to become ADDs/DELETEs for the DAX, MDAX, and SDAX Indices.
    • Two changes could happen between DAX and MDAX while there could be one change between MDAX and SDAX.
    • There could be more changes for the MDAX and SDAX indices as a couple name are lurking close to the border.

    Korea Small Cap Gem #20: BYC

    By Douglas Kim

    • Byc Co Ltd (001460 KS) is the 20th company in our Korea Small Cap Gems series.
    • Estimated value of BYC’s real estate is more than 2 trillion won, which is much higher than its current market cap of 302 billion won. 
    • A large local fund called Truston has been going activist on BYC for more than a year. Plus, BYC’s Chairman Han is being sued by his mum for inheritance recovery. 

    Jiangnan Group (1366 HK): Irrevocable from the Shareholder with a Blocking Stake

    By Arun George

    • The shareholder with a blocking stake has provided an irrevocable to accept Mr Chu Hui (Chairman and CEO)’s offer to privatise Jiangnan (1366 HK) at HK$0.40 per share
    • Key condition is approval by at least 75% of disinterested shareholders (<10% of all disinterested shareholders rejection). There are no other shareholders with a blocking stake. 
    • The price is final and attractive in the context of historical prices and multiples. At the last close, the gross spread is 8.1%. Scheme document likely despatched in mid-April.

    Liberty/Telenet: Intended Offer for Minorities

    By Jesus Rodriguez Aguilar

    • Liberty intends to launch an offer to acquire the minorities in its subsidiary Telenet, taking advantage of the drop in the share price over the last two years.
    • Liberty offers €22/share in cash, cum dividend, 5.9x EV/Fwd EBITDA, a minimum 95% threshold and no MAC with respect to BEL-20 index and shares of Telenet peers prior results announcement.
    • My fair value estimate (DCF based) is €16.2, i.e. 26% downside to the intended offer price. Spread is 5.2%/15.6% (gross/annualised). Cautious long.

    Hindustan Aeronautics (HNAL IN) Offer for Sale: Buy Ahead of Potential MSCI Inclusion

    By Brian Freitas


    💡 Before it’s here, it’s on Smartkarma

    Sign Up for Free

    The Smartkarma Preview Pass is your entry to the Independent Investment Research Network

    • ✓ Unlimited Research Summaries
    • ✓ Personalised Alerts
    • ✓ Custom Watchlists
    • ✓ Company Data and News
    • ✓ Events & Webinars

    Daily Brief Industrials: ZKH Group, Jiangnan, Hindustan Aeronautics Ltd, ACCO Brands, Snap On Inc and more

    By | Daily Briefs, Industrials

    In today’s briefing:

    • ZKH Group IPO: The Bear Case
    • Jiangnan Group (1366 HK): Irrevocable from the Shareholder with a Blocking Stake
    • Hindustan Aeronautics (HNAL IN) Offer for Sale: Buy Ahead of Potential MSCI Inclusion
    • ACCO Brands Is At A Cyclical Discount
    • Snap-on Incorporated: Initiation of Coverage – Business Strategy & Recent Developments

    ZKH Group IPO: The Bear Case

    By Arun George

    • ZKH Group (ZKH US), a leading MRO (maintenance, repair, and operations) procurement service platform in China, is pre-marketing an NYSE IPO to raise US$200-300 million.
    • In ZKH Group IPO: The Bull Case, we highlighted the key elements of the bull case. In this note, we outline the bear case.
    • The key elements of the bear case rest on market share losses, slowing top-line growth, declining take rates and persistent cash burn.

    Jiangnan Group (1366 HK): Irrevocable from the Shareholder with a Blocking Stake

    By Arun George

    • The shareholder with a blocking stake has provided an irrevocable to accept Mr Chu Hui (Chairman and CEO)’s offer to privatise Jiangnan (1366 HK) at HK$0.40 per share
    • Key condition is approval by at least 75% of disinterested shareholders (<10% of all disinterested shareholders rejection). There are no other shareholders with a blocking stake. 
    • The price is final and attractive in the context of historical prices and multiples. At the last close, the gross spread is 8.1%. Scheme document likely despatched in mid-April.

    Hindustan Aeronautics (HNAL IN) Offer for Sale: Buy Ahead of Potential MSCI Inclusion

    By Brian Freitas


    ACCO Brands Is At A Cyclical Discount

    By Pearl Gray Equity and Research

    • ACCO Brands Corporation’s stock is relatively undervalued and presents a lucrative dividend yield worth more than 6%.
    • The company’s recent woes were a consequence of elevated raw material costs.
    • However, key metrics imply that ACCO’s cost base is set to improve.

    Snap-on Incorporated: Initiation of Coverage – Business Strategy & Recent Developments

    By Baptista Research

    • This is our first report on Snap-on Incorporated, a well-known manufacturer and marketer of tools, equipment, diagnostics, repair information and systems solutions in the U.S.
    • The company’s last result was an all-around beat and its organic sales growth was in the double-digits with a particularly strong performance in the Repair Systems & Information Group, high single-digit gains in the Snap-on Tools Group, and low single-digit gains in the Commercial and Industrial Group.
    • Snap-on Tools Group sales were $542.7 million, up from $504.8 million a year ago, with a 9.6% increase in organic sales.

    💡 Before it’s here, it’s on Smartkarma

    Sign Up for Free

    The Smartkarma Preview Pass is your entry to the Independent Investment Research Network

    • ✓ Unlimited Research Summaries
    • ✓ Personalised Alerts
    • ✓ Custom Watchlists
    • ✓ Company Data and News
    • ✓ Events & Webinars

    Daily Brief Industrials: ZKH Group, Jiangnan, Hindustan Aeronautics Ltd, ACCO Brands, Snap On Inc and more

    By | Daily Briefs, Industrials

    In today’s briefing:

    • ZKH Group IPO: The Bear Case
    • Jiangnan Group (1366 HK): Irrevocable from the Shareholder with a Blocking Stake
    • Hindustan Aeronautics (HNAL IN) Offer for Sale: Buy Ahead of Potential MSCI Inclusion
    • ACCO Brands Is At A Cyclical Discount
    • Snap-on Incorporated: Initiation of Coverage – Business Strategy & Recent Developments

    ZKH Group IPO: The Bear Case

    By Arun George

    • ZKH Group (ZKH US), a leading MRO (maintenance, repair, and operations) procurement service platform in China, is pre-marketing an NYSE IPO to raise US$200-300 million.
    • In ZKH Group IPO: The Bull Case, we highlighted the key elements of the bull case. In this note, we outline the bear case.
    • The key elements of the bear case rest on market share losses, slowing top-line growth, declining take rates and persistent cash burn.

    Jiangnan Group (1366 HK): Irrevocable from the Shareholder with a Blocking Stake

    By Arun George

    • The shareholder with a blocking stake has provided an irrevocable to accept Mr Chu Hui (Chairman and CEO)’s offer to privatise Jiangnan (1366 HK) at HK$0.40 per share
    • Key condition is approval by at least 75% of disinterested shareholders (<10% of all disinterested shareholders rejection). There are no other shareholders with a blocking stake. 
    • The price is final and attractive in the context of historical prices and multiples. At the last close, the gross spread is 8.1%. Scheme document likely despatched in mid-April.

    Hindustan Aeronautics (HNAL IN) Offer for Sale: Buy Ahead of Potential MSCI Inclusion

    By Brian Freitas


    ACCO Brands Is At A Cyclical Discount

    By Pearl Gray Equity and Research

    • ACCO Brands Corporation’s stock is relatively undervalued and presents a lucrative dividend yield worth more than 6%.
    • The company’s recent woes were a consequence of elevated raw material costs.
    • However, key metrics imply that ACCO’s cost base is set to improve.

    Snap-on Incorporated: Initiation of Coverage – Business Strategy & Recent Developments

    By Baptista Research

    • This is our first report on Snap-on Incorporated, a well-known manufacturer and marketer of tools, equipment, diagnostics, repair information and systems solutions in the U.S.
    • The company’s last result was an all-around beat and its organic sales growth was in the double-digits with a particularly strong performance in the Repair Systems & Information Group, high single-digit gains in the Snap-on Tools Group, and low single-digit gains in the Commercial and Industrial Group.
    • Snap-on Tools Group sales were $542.7 million, up from $504.8 million a year ago, with a 9.6% increase in organic sales.

    💡 Before it’s here, it’s on Smartkarma

    Sign Up for Free

    The Smartkarma Preview Pass is your entry to the Independent Investment Research Network

    • ✓ Unlimited Research Summaries
    • ✓ Personalised Alerts
    • ✓ Custom Watchlists
    • ✓ Company Data and News
    • ✓ Events & Webinars

    Daily Brief Macro: Equity Watch: Fire-Sale or Outright Fire in US Bank Stocks and more

    By | Daily Briefs, Macro

    In today’s briefing:

    • Equity Watch: Fire-Sale or Outright Fire in US Bank Stocks
    • US: Elevated Inflation and Tight Labour Market to Force Hikes Despite Bank Turmoil
    • UK: Inflation’s Bad Romance
    • CX Daily: Why China’s 2023 Fiscal Policy May Be Less Expansionary Than It Seems

    Equity Watch: Fire-Sale or Outright Fire in US Bank Stocks

    By Andreas Steno

    • Confidence in the US banking system has been under immense stress, and some contagion crossed the Atlantic and struck Europe as well.
    • At the moment, all banks are trading below their 52w highs – some more notably than others (median -25.82%).
    • Deposit flights are driven by the inverted yield curve and particularly regional banks are vulnerable to it.

    US: Elevated Inflation and Tight Labour Market to Force Hikes Despite Bank Turmoil

    By Prasenjit K. Basu

    • With CPI inflation still 6%YoY and core CPI +5.5%YoY (annualised 6%MoM) in Feb’23, the Fed will be obliged to hike 25bp, and likely also reintroduce a reserve requirement for banks. 
    • Unemployment at 3.6% is far below the long-accepted NAIRU of 4.5%, reflected also in average wages still rising 4.6%YoY in Feb’23. M2 declined in Dec’22-Jan’23 but needs to contract more. 
    • A 50bp hike would’ve been warranted, but the collapse of 3 tech-related banks obliges the Fed to be a bit circumspect. The disappearance of CS can’t influence the FOMC decision. 

    UK: Inflation’s Bad Romance

    By Phil Rush

    • The increasing CPI and RPI rates to 10.4% and 13.8% defied UK disinflationary expectations. Price collection on Valentine’s Day isn’t much to blame.
    • The upside news was worryingly broad-based, raising core inflationary pressures. An underlying impulse more than three times the target is painfully excessive.
    • These data reinforce our hawkish view that the BoE needs to raise rates further to break the problematic second-round effects, despite financial stability risks.

    CX Daily: Why China’s 2023 Fiscal Policy May Be Less Expansionary Than It Seems

    By Caixin Global

    • Analysis: Why China’s 2023 fiscal policy may be less expansionary than it seems

    • Xi, Putin call for ‘responsible dialogue’ to end Ukraine crisis

    • Beijing’s deaths outrun births for first time in two decades


    💡 Before it’s here, it’s on Smartkarma

    Sign Up for Free

    The Smartkarma Preview Pass is your entry to the Independent Investment Research Network

    • ✓ Unlimited Research Summaries
    • ✓ Personalised Alerts
    • ✓ Custom Watchlists
    • ✓ Company Data and News
    • ✓ Events & Webinars

    Daily Brief Health Care: Osstem Implant, CSPC Pharmaceutical Group, Quest Diagnostics, Numinus Wellness, Zimmer Biomet Holdings and more

    By | Daily Briefs, Healthcare

    In today’s briefing:

    • MBK/Unison Launch ANOTHER Tender on Osstem Implant (048260 KS) To Squeeze Out Minorities
    • MBK/Unison Capital Announces a Second Tender Offer for Osstem Implant to Take It Private
    • CSPC Pharmaceutical (1093 HK): Double-Digit Sales and Profit Growth in 2022; MRNA Vaccine Approval
    • Quest Diagnostics Incorporated: Detailed Credit Analysis & Financial Strength Evaluation Report
    • Numinus Stands Tall as Others Fall
    • Quest Diagnostics Incorporated: Initiation of Coverage – Business Strategy & Key Drivers
    • Zimmer Biomet Holdings Inc.: Detailed Credit Analysis & Financial Strength Evaluation Report
    • Zimmer Biomet Holdings Inc.: Initiation of Coverage – Acquisition Of Embody & Other Drivers

    MBK/Unison Launch ANOTHER Tender on Osstem Implant (048260 KS) To Squeeze Out Minorities

    By Travis Lundy


    MBK/Unison Capital Announces a Second Tender Offer for Osstem Implant to Take It Private

    By Douglas Kim

    • MBK/Unison Capital consortium announced a second tender offer for Osstem Implant (048260 KS) today in order to take the company private. 
    • The tender offer price is 190,000 won per share, which is the same price as the first tender offer price.
    • The number of shares for the tender offer is 1,654,916, accounting for 10.62% of the outstanding shares.

    CSPC Pharmaceutical (1093 HK): Double-Digit Sales and Profit Growth in 2022; MRNA Vaccine Approval

    By Tina Banerjee

    • CSPC Pharmaceutical Group (1093 HK) reported 11% YoY revenue growth in 2022. The finished drug business maintained steady growth in 2022, with a continued increase in contribution from new products.
    • Within the next 5 years, more than 40 innovative drugs are expected to be approved, which will provide continuous momentum for the company’s development.
    • In March 2023, CSPC’s COVID-19 mRNA vaccine SYS6006 has become the first independently developed mRNA vaccine product in China that has been granted for emergency use.

    Quest Diagnostics Incorporated: Detailed Credit Analysis & Financial Strength Evaluation Report

    By Baptista Research

    • Quest Diagnostics Incorporated is a well-known provider of diagnostic information services.
    • The company produced significant double-digit growth in prenatal genetics and pharmaceutical services for sophisticated diagnostics.
    • Baptista Research looks to evaluate the different credit strengths and credit risks of the company as well as a line-by-line analysis of the financial statements of the company for the past four years.

    Numinus Stands Tall as Others Fall

    By Water Tower Research

    • Opportunity knocks. In a period of sector upheaval, Numinus remains a steadfast business, with operating profitability in clear line of sight.
    • The company is well positioned to benefit from reduced competition.
    • Field Trip, Delic clinic closures. On March 15, 2023, Field Trip Health & Wellness announced that it will be closing five clinics located in Chicago, Washington DC, Seattle, San Diego, and Fredericton, the majority of its active nine clinics across North America, to “reduce expenditures and preserve capital”.

    Quest Diagnostics Incorporated: Initiation of Coverage – Business Strategy & Key Drivers

    By Baptista Research

    • This is our first report on leading diagnostic service provider, Quest Diagnostics Incorporated.
    • The company produced significant double-digit growth in prenatal genetics and pharmaceutical services for sophisticated diagnostics.
    • Agilent Technologies further signed an agreement with Quest to make the Agilent Resolution ctDx FIRST liquid biopsy next-generation sequencing (NGS) test available to providers and patients across the U.S.

    Zimmer Biomet Holdings Inc.: Detailed Credit Analysis & Financial Strength Evaluation Report

    By Baptista Research

    • Zimmer Biomet Holdings is a global medical technology giant.
    • The management has been seeing positive comps across 2022 and saw good growth in major joints, with their entire global hip and knee business expanding well.
    • Baptista Research looks to evaluate the different credit strengths and credit risks of the company as well as a line-by-line analysis of the financial statements of the company for the past four years.

    Zimmer Biomet Holdings Inc.: Initiation of Coverage – Acquisition Of Embody & Other Drivers

    By Baptista Research

    • This is our first report on the global medical technology behemoth Zimmer Biomet Holdings.
    • They observed another quarter of year-over-year growth in major joints, with their entire global hip and knee business expanding by more than 8% and 10% on an ex FX basis.
    • We initiate coverage on the stock of Zimmer Biomet Holdings, Inc. with a ‘Hold’ rating.

    💡 Before it’s here, it’s on Smartkarma

    Sign Up for Free

    The Smartkarma Preview Pass is your entry to the Independent Investment Research Network

    • ✓ Unlimited Research Summaries
    • ✓ Personalised Alerts
    • ✓ Custom Watchlists
    • ✓ Company Data and News
    • ✓ Events & Webinars

    Most Read: Tokyo Stock Exchange Tokyo Price Index Topix, S.M.Entertainment Co, Bellevue Gold, Rakuten, Indus Towers, Rakuten Bank, Sumitomo Mitsui Financial Group, Osstem Implant, ASICS Corp and more

    By | Daily Briefs, Most Read

    In today’s briefing:

    • The BIG March 2023 “Wednesday Thursday Trade”
    • S.M. Entertainment: Proration Musings
    • S&P/​​​​​​ASX Index Rebalance Preview: Changes from Now to June
    • Rakuten Bank (5838 JP) IPO: Listing in April, TPX Inclusion in May, MSCI SC in August
    • India: AMFI Stock Reclassification Preview (June 2023)
    • Rakuten Bank (5838 JP) – Another Net-Bank IPO, This One With TOPIX and Other Index Inclusions
    • Japan Banks: Markets Overreact to SVB’s Collapse
    • MBK/Unison Launch ANOTHER Tender on Osstem Implant (048260 KS) To Squeeze Out Minorities
    • MBK/Unison Capital Announces a Second Tender Offer for Osstem Implant to Take It Private
    • ASICS (7936) | Running Is Recession Proof

    The BIG March 2023 “Wednesday Thursday Trade”

    By Travis Lundy

    • Every year it’s the same trade. But it isn’t really. But it kinda is. This year it is Wednesday and Thursday. There are risks to the analysis – notably allocation.
    • But, ceteris paribus, it is still possibly a ¥1,580,876,450,407 buying spree to take place on one day into the close later this month. Or something close to it.
    • And for a two-day period, over the last ten years, the average return is 1.60% on these two days with a 9:1 win ratio. Lots of angles here.

    S.M. Entertainment: Proration Musings

    By David Blennerhassett

    • After HYBE (352820 KS) conceded to Kakao Corp (035720 KS) earlier this month, S.M.Entertainment Co (041510 KS)‘s shares have declined 23%. 
    • Kakao’s Partial Offer of  ₩150,000/share closes on the 26 March. 
    • Unadjusted proration is 36.8%, conservatively rising to 48.5%. It may settle at 61% if HYBE maintains its position – but that is probably a tad optimistic. 

    S&P/​​​​​​ASX Index Rebalance Preview: Changes from Now to June

    By Brian Freitas


    Rakuten Bank (5838 JP) IPO: Listing in April, TPX Inclusion in May, MSCI SC in August

    By Brian Freitas

    • Rakuten Bank (EBANKZ JP)‘s listing has been approved by the JPX and the stock is expected to start trading on the Prime Market from 21 April.
    • News reports indicate a raise of US$800mn (JPY 106.8bn) at the mid-point of the IPO range, valuing the company at JPY 305bn (US$2.3bn). 
    • The stock should be added to the TPX INDEX at the close on 30 May where trackers will need to buy over 14% of the stock issued in the IPO.

    India: AMFI Stock Reclassification Preview (June 2023)

    By Brian Freitas

    • Nearly halfway through the review period, we see 10 stocks moving from MidCap to LargeCap and vice versa, and 9 stocks moving from SmallCap to MidCap and vice versa.
    • Financials are poised to be the biggest gainers in the reshuffle with 6 stocks moving from MidCap to LargeCap and 5 stocks moving from SmallCap to MidCap.
    • Over the last 6 months, stocks expected to migrate upward have outperformed stocks that are expected to migrate downward., though there has been a downward drift this year.

    Rakuten Bank (5838 JP) – Another Net-Bank IPO, This One With TOPIX and Other Index Inclusions

    By Travis Lundy


    Japan Banks: Markets Overreact to SVB’s Collapse

    By Oshadhi Kumarasiri

    • Following the collapse of SVB and Signature Bank last week, Japan’s big four banks have fallen by around 15% due to their exposure to US government bonds.
    • However, the Japanese banks have managed the interest rate risk far better than the collapsed US banks and therefore, we feel the price drop is unwarranted.
    • With Japan likely to scrap its zero rates policy, we think this could be a rather intriguing opportunity to make generous gains on the long side in Japan’s banking sector.

    MBK/Unison Launch ANOTHER Tender on Osstem Implant (048260 KS) To Squeeze Out Minorities

    By Travis Lundy


    MBK/Unison Capital Announces a Second Tender Offer for Osstem Implant to Take It Private

    By Douglas Kim

    • MBK/Unison Capital consortium announced a second tender offer for Osstem Implant (048260 KS) today in order to take the company private. 
    • The tender offer price is 190,000 won per share, which is the same price as the first tender offer price.
    • The number of shares for the tender offer is 1,654,916, accounting for 10.62% of the outstanding shares.

    ASICS (7936) | Running Is Recession Proof

    By Mark Chadwick

    • Good news from Nike’s Q3 report, which bodes well for Asics March quarter
    • Why was Nike’s stock down? Margins were down 330bps on inventory mark downs
    • Running is recession proof according to the footwear makers themselves

    💡 Before it’s here, it’s on Smartkarma

    Sign Up for Free

    The Smartkarma Preview Pass is your entry to the Independent Investment Research Network

    • ✓ Unlimited Research Summaries
    • ✓ Personalised Alerts
    • ✓ Custom Watchlists
    • ✓ Company Data and News
    • ✓ Events & Webinars

    Daily Brief China: International Housewares Retail, Pinduoduo, Taste Gourmet, Fu Shou Yuan, Vedanta Resources, Growatt Technology, Onewo, JOYY and more

    By | China, Daily Briefs

    In today’s briefing:

    • 1373 HK: Value Play 8x PE, Dividend Yield ~10%, 20% of Mkt Cap in Cash
    • Pinduoduo: Cost Cutting Wearing Out, Margins Heading Towards Our Steady State Target of 6-7%
    • Shortlist of High Conviction Ideas – Income, Value, Margin of Safety
    • Fu Shou Yuan (1448.HK) – 2022 Results Missed Expectations, but the Outlook Remains Positive
    • Morning Views Asia: Sino-Ocean Service, Vedanta Resources
    • Growatt Technology Pre-IPO – Refiling Updates – Still Running Strong
    • Onewo Space-Tech IPO Lock-Up – Company, Parent and Cornerstones Could Eventually Sell
    • [PDD US]: Slowing Growth but Still Best-In-Class, Cut TP Maintain BUY.
    • [YY US]: Maintain SELL for Cost Rebound and Competition

    1373 HK: Value Play 8x PE, Dividend Yield ~10%, 20% of Mkt Cap in Cash

    By Sameer Taneja

    • International Housewares Retail (1373 HK) is an interesting value/growth (5-10% CAGR) play with a high-dividend yield of >10%, trading at 8.1x FY23 PE. 
    • The claim to fame for this company is the investment of legendary HK mid/small cap investor David Webb (who has a 6.9% stake in this company). 
    • At a market cap of 2 bn HKD, the company has about 400 mn HKD net cash (20% of market cap), making it 6.9x ex-cash PE.

    Pinduoduo: Cost Cutting Wearing Out, Margins Heading Towards Our Steady State Target of 6-7%

    By Oshadhi Kumarasiri

    • With the impact of cost-cutting and monetisation wearing out, consensus looks overly aggressive to expect revenue and OP CAGRs of 24% and 35% respectively over the next two years.
    • Based on Pinduoduo (PDD US)’s revenue and cost trends discussed below, we think the steady state OP margin could be substantially lower than consensus.
    • Expecting consensus to downgrade expectations, we don’t think it is worthwhile paying up to 45.0x FY+2 OP (on our steady-state OP margin) for Pinduoduo at its current EV of $80.5bn.

    Shortlist of High Conviction Ideas – Income, Value, Margin of Safety

    By Sameer Taneja


    Fu Shou Yuan (1448.HK) – 2022 Results Missed Expectations, but the Outlook Remains Positive

    By Xinyao (Criss) Wang

    • Fu Shou Yuan (1448 HK)’s 2022 results were below our expectations. Affected by the 22Q4 pandemic, the performance recovery in 22H2 was lower than expected. 
    • The high demand due to soaring death rate since 22Q4 would be reflected in 23H1 results. Together with low base last year, strong performance rebound in 23H1 is worth expecting.
    • The reason behind short-term trade and long-term hold is different. But considering the Company has no obvious flaws in its long logic, every pullback can be a good buying opportunity.

    Morning Views Asia: Sino-Ocean Service, Vedanta Resources

    By Charles Macgregor

    Lucror Analytics Morning Views comprise our fundamental credit analysis, opinions and trade recommendations on high yield issuers in the region, based on key company-specific developments in the past 24 hours. Our Morning Views include a section with a brief market commentary, key market indicators and a macroeconomic and corporate event calendar.


    Growatt Technology Pre-IPO – Refiling Updates – Still Running Strong

    By Ethan Aw

    • Growatt Technology (1833969D CH) is looking to raise about US$1bn in its upcoming Hong Kong IPO. 
    • Growatt Technology is a global distributed energy solution provider, specializing in sustainable energy generation, storage and consumption, as well as energy digitalization. 
    • In our previous notes, we looked at the company’s past performance, peer comparison and shared our thoughts on valuation. In this note, we will talk about its refiling updates.

    Onewo Space-Tech IPO Lock-Up – Company, Parent and Cornerstones Could Eventually Sell

    By Sumeet Singh

    • Onewo (2602 HK) (OST) had raised around US$730m in its Hong Kong IPO in Sep 2022. Its six-month lockup is set to expire soon.
    • OST is a property management service provider in China, primarily owned by China Vanke (H) (2202 HK)
    • In this note, we will talk about the lock-up dynamics and updates since our last note.

    [PDD US]: Slowing Growth but Still Best-In-Class, Cut TP Maintain BUY.

    By Shawn Yang

    • PDD reported C4Q22 total revenue and non-GAAP net income (5.1%) and 8.4% higher than cons. Topline miss mainly comes from the deceleration of online marketplace services. 
    • We expect that PDD’s domestic eCommerce will experience slowdown in growth.  Temu is likely to grow GMV rapidly with high losses from branding and subsidies.
    • PDD still outpaces its peers including JD, BABA and Shein, in both domestic and oversea markets. Maintain BUY rating on PDD with TP of US$95, which implies 24x P/2023E.

    [YY US]: Maintain SELL for Cost Rebound and Competition

    By Shawn Yang

    • JOYY reported 4Q22 top line of US$ 605 mn, beat our est. by 3.2%, and GAAP net income turned negative mostly due to investment loss. 
    • With limited catalyst for top line, increasing operating expense and content cost to cope with competition would put pressure on bottom line. 
    • Maintain SELL rating and cut TP to US$ 23.7, implying 12.6X PE in 2023.

    💡 Before it’s here, it’s on Smartkarma

    Sign Up for Free

    The Smartkarma Preview Pass is your entry to the Independent Investment Research Network

    • ✓ Unlimited Research Summaries
    • ✓ Personalised Alerts
    • ✓ Custom Watchlists
    • ✓ Company Data and News
    • ✓ Events & Webinars